Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aileron Therapeutics Inc ALRN

Healthcare Biotechnology
Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib... see more

Recent & Breaking News (NDAQ:ALRN)

Aileron Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire January 4, 2022

Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. Grubbs

GlobeNewswire December 20, 2021

Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

GlobeNewswire November 12, 2021

Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924's Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity

GlobeNewswire October 7, 2021

Aileron Therapeutics Announces Presentation of New Preclinical Data at Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021

GlobeNewswire September 30, 2021

Aileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress 2021 Supporting ALRN-6924's Best-in-Class Potential as a Chemoprotective Agent

GlobeNewswire September 16, 2021

Aileron Therapeutics to Present New Clinical Data at ESMO Virtual Congress 2021 Supporting Novel, Selective Chemoprotective Agent ALRN-6924

GlobeNewswire September 10, 2021

Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference

GlobeNewswire September 7, 2021

Aileron Therapeutics Presents Initial Findings from Ongoing Healthy Volunteer Study of ALRN-6924 at ISEH 50th Annual Scientific Meeting

GlobeNewswire August 27, 2021

Aileron Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire August 11, 2021

Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2021

GlobeNewswire July 8, 2021

Aileron Therapeutics Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

GlobeNewswire July 1, 2021

Aileron Therapeutics to be Added to the Russell Microcap® Index

GlobeNewswire June 24, 2021

Aileron Therapeutics to Host KOL Virtual Investor Event Discussing Opportunity for New Paradigm to Protect Cancer Patients from Chemotherapy-Induced Toxicities

GlobeNewswire May 19, 2021

Aileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire May 11, 2021

Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights

GlobeNewswire March 24, 2021

Aileron Therapeutics to Present at 2021 H.C. Wainwright Global Life Sciences Conference

GlobeNewswire March 4, 2021

Aileron Therapeutics Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

GlobeNewswire March 2, 2021

Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures, BVF Partners, L.P. and Maven Investment Partners

GlobeNewswire January 11, 2021

Aileron Therapeutics Announces $35.9 Million Registered Direct Offering

GlobeNewswire January 6, 2021